Containerless Plasma Synthesis of Amorphous Pharmaceuticals
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing amorphous pharmaceutical compounds are inefficient, with low yield and limited scalability, making it difficult to create bulk amorphous forms of drugs, especially those with low molecular weights like aspirin, which are often insoluble in their crystalline form.
Innovation Solution
A method involving containerless processing using levitation techniques to prevent nucleation, allowing for the production of amorphous materials by evaporating solvents from solutions or melting solids in nucleation-free environments, resulting in high yields of amorphous compounds with enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional pharmaceutical processes (melt quenching, freeze drying, milling) are used to produce amorphous materials, then amorphous forms can be obtained, but the conversion yield is low (less than 75%, typically about 40%) and production is limited to small scales (less than 500 milligrams)
Solution Approach 1:
The patent replaces conventional mechanical processing methods (milling, granulation, container-based melt quenching) with an electromagnetic field-based plasma process. The plasma environment provides a unique reaction zone where materials are processed without mechanical contact, eliminating the limitations of conventional methods and enabling high-yield bulk production of amorphous materials with superior phase purity
Solution Approach 2:
The patent utilizes plasma parameters (temperature, energy density, reaction time) to control the formation of amorphous phases. By adjusting plasma processing conditions, the method achieves complete conversion (greater than 75%, typically 80-95%) to amorphous phase while maintaining scalability from milligram to kilogram quantities
2Ease of manufacture
If container-based melt quenching is used, then amorphous materials can be produced, but extrinsic nucleation sites on container surfaces cause crystallization, reducing amorphous phase purity
Solution Approach 1:
The patent extracts the harmful element (container walls with nucleation sites) from the manufacturing process by using a plasma environment where materials are processed in a containerless manner. This eliminates the source of extrinsic nucleation that causes unwanted crystallization, resulting in superior amorphous phase purity while maintaining ease of manufacture through a streamlined plasma-based process
3Adaptability or versatility
If conventional methods are used for low molecular weight drugs (e.g., aspirin with 189 Daltons), then crystalline forms are obtained, but amorphous forms are difficult or impossible to produce
Solution Approach 1:
The patent employs a universal plasma processing approach that can handle materials across a wide range of molecular weights and chemical compositions. The plasma environment provides uniform energy distribution and controlled reaction conditions that enable successful amorphous phase formation for low molecular weight drugs (like aspirin with 189 Daltons) as well as larger molecules, making the method universally applicable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high conversion rates of amorphous materials, up to 100% in some cases, with increased bioavailability and solubility compared to crystalline forms, and enables the production of bulk quantities of stable amorphous pharmaceuticals.
Implementation Method 1
containerless processing using levitation techniques to prevent nucleation
Implementation Method 2
evaporating solvents from solutions or melting solids in nucleation-free environments
Implementation Method 3
melting solids in nucleation-free environments
Data Source
AI summary
The invention provides a method for producing a mixture of amorphous compounds, the method comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point. Also provided is a method for transforming solids to amorphous material, the method comprising heating the solids in an environment to form a melt, wherein the environment contains no nucleation points; and cooling the melt in the environment.